{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 67 of 122', 'All adverse events from the start of study treatment must be documented on the adverse', \"event case report form and in the subject's source documents. Any event occurring during\", 'screening and before the first dose must also be documented on the appropriate case report', \"form and in the subject's source documents.\", '8.6.2', 'Reporting for Serious Adverse Events, Adverse Events of Interest, and Other', 'Notable Events', 'Serious adverse events, adverse events of interest, and other notable events for all subjects', '(ie, both treatment groups) require rapid reporting within 24 hours of the study site', \"personnel's knowledge of the event, regardless of the investigator assessment of the\", 'relationship of the event to study product.', 'The contact information for submission of information for reportable events is as follows:', 'Name:', 'ProPharma Group', 'Email:', 'clinicalsafety@propharmagroup.com', 'The initial report should include, at minimum, the following:', 'Study number (ARC009)', 'Site name and number', 'Investigator name', 'Subject ID number, sex, and age (unless omitted per local regulations)', 'Details of study treatment', 'The date of the report', 'A description of the event (event term, severity)', 'Initial reporting should not be delayed, and additional follow-up reports may be submitted as', 'new information becomes available. Follow-up reports should include date of onset, study', 'site/hospital records, discharge summary, resolution date, treatment and action for the event,', 'assessment of relatedness to study product, and any other applicable information.', '8.6.2.1', 'Serious Adverse Events Reporting', 'Study site personnel will report serious adverse events to the sponsor or designee using a', 'serious adverse event report form in accordance with the information requested on the form.', 'Serious adverse events reported to the investigator after the safety reporting period are to be', 'reported to the sponsor if the investigator assesses the event as related to the study product.', 'If a subject dies, the serious adverse event report should include the cause of death as the', 'event term (with fatal outcome), whether the event leading to death was related to study']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 68 of 122', 'product, the autopsy findings if available, and any other supporting data (eg, death certificate,', 'hospital/study site notes).', '8.6.2.1.1', 'Expedited Reporting of Serious Adverse Events by the Sponsor and', 'Periodic Reporting', 'The sponsor will determine whether a serious adverse event meets the criteria for expedited', 'reporting to regulatory authorities, ECs, and investigators, as applicable in accordance with', 'International Council for Harmonisation (ICH) E2A and ICH E6, and will ensure that reports', 'are provided in compliance with the required timing.', 'Additionally, the sponsor will submit to regulatory authorities all safety updates and periodic', 'reports as required by applicable national and international requirements including but not', 'limited to ICH E6 and ICH E2F.', '8.6.2.2 Adverse Events of Interest Reporting', 'Nonserious adverse events of interest will require rapid reporting (within 24 hours)', 'regardless of severity, causality assessment, and where the event occurred (at the study site or', 'elsewhere). Adverse events of interest include the following, and details for each are', 'provided in the referenced sections:', 'Anaphylaxis (Section 8.5.1.1).', 'GI adverse events with prolonged dose interruption defined as withholding study', 'product for > 7 days due to GI adverse events, or GI adverse events that result in early', 'discontinuation or are ongoing at early discontinuation (Section 8.5.6.2).', 'Accidental/nonaccidental food allergen exposure (Section 8.5.6.3). Rapid reporting is', 'required regardless of whether the exposure resulted in an adverse event.', 'Adverse events with severe symptoms (Section 8.5.6.4). Intended for adverse events', 'that do not meet the criteria for other adverse events of interest.', 'Use of epinephrine (Section 8.5.6.5). Use of epinephrine for a serious adverse event', 'or other event requiring rapid reporting (eg, anaphylaxis, food allergen exposure)', 'does not need to be reported separately.', 'Adverse events of interest are to be reported using a nonserious adverse event of interest', 'report form. Adverse events of interest meeting serious adverse event criteria are to be', 'reported as serious adverse events.', '8.6.2.3', 'Other Notable Events Reporting', 'Reportable events in this category include pregnancy and overdose.', 'Pregnancy: Although pregnancy is not considered an adverse event, pregnancy must be', 'reported on a pregnancy notification form. The pregnancy will be followed to delivery or']\n\n###\n\n", "completion": "END"}